Can-Fite BioPharma Ltd.: Form 20-F for the period ended Dec 31, 2021
Filed with the SEC on Mar 24, 2022 and accepted by EDGAR at Mar 24, 2022, 09:38 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2021-01-01 to 2021-12-31 | $853.0k | us-gaap:Revenues |
| Research and development | 12 months2021-01-01 to 2021-12-31 | $9.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2021-01-01 to 2021-12-31 | −$12.8m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2021-01-01 to 2021-12-31 | −$12.6m | us-gaap:NetIncomeLoss |
| Operating cash flow | 12 months2021-01-01 to 2021-12-31 | −$9.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2021-01-01 to 2021-12-31 | $11.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2021-01-01 to 2021-12-31 | $2.6m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2021-12-31 | $4.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-12-31 | $20.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-12-31 | $20.3m | us-gaap:Assets |
| Current liabilities | At period end2021-12-31 | $2.7m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2021-12-31 | $14.4m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2021-12-31 | 815,746,293 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001213900-22-014672. Last ingested by Listed: Nov 2, 2026, 07:04 ET. Listed shows no prices and gives no investment advice.